Our findings suggest that an assessment of the BDNF/TrkB and/or PTX3 expression status in gastric tumors allows clinicians to predict metastatic potential and improve the prognosis of patients with advanced gastric cancers and could further guide the development of better therapeutic regimens to improve outcomes in patients with gastric cancer. The gene discussed is BDNF; the disease is gastric cancer.